A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE015 (POL) · Dr. Ito
consented 2023-07-19
Adverse events
Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-08-02 (study day 7); relationship: not assessed
Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-09-16 (study day 52); relationship: not assessed
Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-09-23 (study day 59); relationship: N
Grade 2 Constipation — outcome: RECOVERED/RESOLVED; onset 2023-09-26 (study day 62); relationship: not assessed
Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-09-30 (study day 66); relationship: not assessed
Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-10-06 (study day 72); relationship: Y
Grade 1 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2023-12-26 (study day 153); relationship: not assessed
Grade 2 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2024-03-22 (study day 240); relationship: not assessed
Data queries
No data queries.